Human immunodeficiency virus and β-thalassemia major: A "competition of guilt" for pulmonary arterial hypertension. Report of a case and a review of the literature

Hemoglobin

Volumn 34, Issue 1, 2010, Pages 61-66

  Derchi, Giorgio ^a   Lai, Maria E ^b   Marcaccini, Paolo ^a   Carta, Maria P ^b   Vacquer, Stefania ^b  

^a GALLIERA HOSPITAL   (Italy)

^b Osp Regionale per le Microcitemie   (Italy)

Author keywords

Thalassemia major ( TM); Heart failure; Human immunodeficiency virus (HIV); Pulmonary arterial hypertension (PAH)

Indexed keywords

LAMIVUDINE; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

BETA THALASSEMIA; BONE MARROW TOXICITY; CARDIOMYOPATHY; CD4 LYMPHOCYTE COUNT; CHELATION THERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; HEART RIGHT VENTRICLE FUNCTION; HEMOGLOBINOPATHY; HEMOLYTIC ANEMIA; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; REVIEW; SPIROMETRY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHELATING AGENTS; FEMALE; HIV INFECTIONS; HUMANS; HYPERTENSION, PULMONARY;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 76449106785     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630260903547765     Document Type: Review

References (24)

1. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(12)(Suppl. S):5S-12S.
2. Zuber JP, Calmy A, Evison JM, et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis. 2004;38(8):1178-1185.
3. Derchi G, Fonti A, Forni GL, et al. Pulmonary hypertension in patients with thalassemia major. Am Heart J. 1999;138(2, Pt 1):384.
4. Grisaru D, Rachmilewitz EA, Mosseri M, et al. Cardiopulmonary assessment in b-thalassemia major. Chest. 1990;98(5):1138-1142.
5. Aessopos A, Farmakis D, Hatziliami A, et al. Cardiac status in well-treated patients with thalassemia major. Eur J Haematol. 2004;73(5):359-366.
6. Derchi G, Formisano F, Lamagna M, et al. Incidence of pulmonary hypertension in hemoglobinopathic patients without left ventricular dysfunction. Blood. 2005;106(11) (abstract).
7. Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus associated pulmonary arterial hypertension. Am J Respire Crit Care Med. 2003;167(10):1433-1439.
8. Marecki JC, Cool CD, Beckey VE, et al. HIV-1 Nef protein is present a the site of plexiform lesions in patients with HIV-related pulmonary hypertension and induces a program altered endothelial cell growth and survival in vitro. Proc Am Thorac Soc. 2006;3:A476.
9. Cool CD, Rai PR, Yeager ME, et al. Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med. 2003;349(12):1113-1122.
10. Gutiérrez F, Masia M, Padilla S, et al. Occult lymphadenopathic Kaposi's sarcoma associated with severe pulmonary hypertension: a clinical hint about the potential role of HHV-8 in HIV-related pulmonary hypertension? J Clin Virol. 2006;37(2):79-82.
11. Eddahibi S, Humbert M, Sediame S, et al. Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effects of prostacyclin therapy. Am J Respir Crit Care Med. 2000;162(4, Pt 1):1493-1499.
12. Aoki Y, Jaffe ES, Chang Y, et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcomaassociated herpesvirus-encoded interleukin-6. Blood. 1999;93(12):4034-4043.
13. Jison ML, Gladwin MT. Hemolytic anemia-associated pulmonary hypertension of sickle cell disease and the nitric oxide/arginine pathway. Am J Respir Crit Care Med. 2003;168(1):3-4.
14. Gladwin MT, Kato GJ. Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2005;51-57.
15. Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension and mortality in sickle cell disease. JAMA. 2005;294(1):81-90.
16. Rother RP, Bell L, Hillmen P, et al. The clinical sequeleae of intravascular hemolysis and extracellular plasma haemoglobin: a novel mechanism of human disease. JAMA. 20056;293(13):1653-1662.
17. AtichartakarnV, Likittanasombat K, Chuncharunee S, et al. Pulmonary arterial hypertension in previously splenectomized patients with b-thalassemic disorders. Int J Hematol. 2003;78(2):139-145.
18. Zakynthinos E, Vassilakopoulos T, Kaltsas P, et al. Pulmonary hypertension, interstitial lung fibrosis, and lung iron deposition in thalassemia major. Thorax. 2001;56(9):737-739.
19. Du ZD, Roguin N, Milgram E, et al. Pulmonary hypertension in patients with thalassemia major. Am Heart J. 1997;134(3):532-537.
20. Barnett CF, Hsue PY, Machado RF. Pulmonary hypertension. An increasingly recognized complication of hereditary haemolytic anemias and HIV infection. JAMA. 200823;299(3):324-331.
21. Aliyu ZY, Kato GJ, Taylor J, 4th. Sickle cell disease and pulmonary hypertension in Africa: a global perspective and review of epidemiology, pathophysiology and management. Am J Hematol. 2008;83(1):63-70.
22. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425-1436.
23. Derchi G, Forni GL, Formisano F, et al. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica. 2005;90(4):452-458.
24. Lin EE, Gladwin MT, Machado RF. Pulmonary hypertension in patients with hemoglobinopathies: could a mechanism for dysfunction provide an avenue for novel therapeutics? Haematologica. 2005;90(4):441-443.